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ABSTRACT

Objectives This study aims to determine the proportion
of real-world patients with myocardial infarction (MI)
who would have been eligible for the PEGASUS-TIMI 54
(Prevention of Cardiovascular Events in Patients with
Prior Heart Attack Using Ticagrelor Compared to Placebo
on a Background of Aspirin-Thrombolysis in Myocardial
Infarction 54) trial, to characterise their current use of
P2Y12 inhibitors and to explore the estimated costs and
ischaemic event consequences of increasing P2Y12
inhibitor use among these patients.
Methods In the US national ACTION Registry–GWTG
(Acute Coronary Treatment and Intervention Outcomes
Network Registry–Get With The Guidelines), we identified
273 328 patients with MI and determined the proportion
that would have met the eligibility criteria for the PEGASUS
trial. We described longitudinal P2Y12 inhibitor use among
patients eligible for PEGASUS and estimated the cost and
ischaemic consequences of increasing P2Y12 use among
eligible patients.
Results A total of 112 222 (41.1%) patients with MI in
ACTION Registry–GWTG met eligibility for the PEGASUS
trial. Among 83 871 eligible patients with pharmacy claims
data, 23 042 (27.5%) were on a P2Y12 inhibitor at 1 year,
9661 (11.5%) at 2 years and 5246 (6.3%) at 3 years, with
the majority (79.2%) of these patients on clopidogrel.
The use of ticagrelor in eligible patients not yet on a
P2Y12 inhibitor at 1 year post-MI would cost an estimated
US$885 000 per MI, stroke or cardiovascular death averted
over a 3-year time horizon, while the use of clopidogrel
would cost an estimated US$19 800 per ischaemic event
averted.
Conclusion In contemporary clinical practice, a minority
of patients are on a P2Y12 inhibitor beyond 1-year post-MI.
Applying PEGASUS trial findings to clinical practice would
result in a large increase in P2Y12 inhibitor use, with a cost
per ischaemic event averted that is strongly influenced by
the choice of therapy.

INTRODUCTION
The activated platelet is a key contributor to the
pathobiology of acute coronary events.1 Dual
antiplatelet therapy (DAPT) with aspirin, and
a P2Y12 inhibitor has been shown to reduce
the risk of ischaemic events in patients with an
acute coronary syndrome (ACS).2 The benefit
of long-term P2Y12 therapy for patients with
stable cardiovascular disease is less clear. A

KEY QUESTIONS
What is already known about this subject?
The PEGASUS-TIMI 54 (Prevention of Cardiovascular
Events in Patients with Prior Heart Attack Using
Ticagrelor Compared to Placebo on a Background
of Aspirin-Thrombolysis in Myocardial Infarction 54)
trial demonstrated a reduction in ischaemic events
following P2Y12 inhibition with ticagrelor among
patients with a prior myocardial infarction (MI). The
implications of these findings for clinical practice are
unknown.

What does this study add?
Less than half of all stable patients with post-MI in
routine US clinical practice met the PEGASUS eligibility
criteria. Furthermore, P2Y12 inhibitors were infrequently
used in the long-term management of patients with
MI in the ACTION Registry–GWTG (Acute Coronary
Treatment and Intervention Outcomes Network
Registry–Get With The Guidelines). The estimated cost
per ischaemic event averted with increasing P2Y12
inhibitor use is nearly 45-fold larger with long-term
ticagrelor than with generic clopidogrel.

How might this impact on clinical practice?
Applying PEGASUS trial findings to clinical practice
would result in a large increase in P2Y12 inhibitor
use. Given the cost implications for different P2Y12
inhibitors, additional study of long-term P2Y12 inhibitors
on patient outcomes and cost of care is needed to
guide optimal use of this therapy in clinical practice.

randomised trial of long-term clopidogrel on
background aspirin therapy did not demonstrate benefit in a broad population at risk
of atherosclerotic events.3 However, post hoc
analyses suggested the addition of clopidogrel to aspirin resulted in benefit for certain
patient subgroups, including those with a
prior history of myocardial infarction (MI).4
These findings implicated potential benefit
of long-term DAPT in specific subgroups of
patients at high risk of ischaemic events.5–7
Newer generation P2Y12 receptor antagonists are characterised by greater platelet
inhibition, less variability in clinical
response, and superior efficacy compared
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with clopidogrel following an ACS.8 9 The recent
PEGASUS-TIMI 54 (Prevention of Cardiovascular
Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of
Aspirin-Thrombolysis in Myocardial Infarction 54)
trial sought to determine whether the benefit of ticagrelor, a newer generation P2Y12 inhibitor, extends to
stable patients with a remote history of MI.10 The study
found that ticagrelor use, with background aspirin
therapy, resulted in a 1.2% absolute reduction in the
rate of cardiovascular death, MI or stroke over 3 years
compared with aspirin alone.11
Although the PEGASUS trial findings suggest an
intriguing opportunity to improve outcomes of patients
with prior MI, patients seen in routine clinical practice
may differ from those enrolled in clinical trials.12 Consequently, the prevalence of stable patients with MI in
US clinical practice who would meet PEGASUS enrolment criteria for long-term therapy with P2Y12 therapy is
unknown. In addition, given the prior post hoc analysis
of long-term therapy with clopidogrel4 and recent data
demonstrating benefit to prolonged P2Y12 following PCI,13
many patients with a remote history of MI may already be
on some form of long-term P2Y12 inhibitor. Finally, clopidogrel became available as a generic prescription in May,
2012, while ticagrelor remains on patent until 2018. As a
result, there may be cost differences in consideration of
long-term P2Y12 inhibitor use.
Answers to these questions can be measured using
clinical registries, such as the American College of Cardiology (ACC) National Cardiovascular Disease Registry
(NCDR) programs. The ACC has recently launched the
Research to Practice initiative (formerly titled Rapid
Registry Response), which facilitates rapid analysis of
registry data to understand how clinical trials, such as
PEGASUS, inform clinical practice.14 Accordingly, we
used this initiative and the NCDR ACTION Registry
to determine the proportion of real-world patients
with post-MI who would be eligible for the PEGASUS
trial, characterise their use of P2Y12 inhibitors and
model the costs and ischaemic clinical consequences of
adding long-term P2Y12 therapy in accordance with the
PEGASUS trial.
METHODS
Data source
The NCDR ACTION Registry–GWTG (Acute Coronary Treatment and Intervention Outcomes Network
Registry–Get With The Guidelines) is a US national
quality improvement registry of ST-segment elevation
MI (STEMI) and non-STEMI (NSTEMI) patients.15
Trained staff extracts data from medical records into a
Web-based case record without direct patient contact.
A listing of specific data fields and their definitions is
available (http://www.ncdr.com/WebNCDR/ACTION/
Elements.aspx). Our study cohort was derived from
patients presenting with their first MI in the registry from
2

1 October 2010 to 30 April 2013 at ACTION Registry–
GWTG participating hospitals.
To identify long-term use of DAPT, data from ACTION
Registry–GWTG were linked with pharmacy claims data
from Symphony Health Solutions, a multichannel claims
data resource that includes all payer types, including cash
self-pay, and covers pharmacy activity in all 50 US states.
The data warehouse captures dispensed prescription
drugs from claims clearing-houses, retail pharmacies and
prescription benefit managers for approximately 70%
of US retail pharmacy transactions. Records comprise
National Council for Prescription Drug Program
formatted claims, which include the date of a given pharmacy fill, national drug code, drug name and dosage, as
well as other standardised fields.16
Patient population
We replicated the inclusion and exclusion criteria from
the PEGASUS-TIMI 54 trial to identify patients for whom
the findings of this trial may apply.10 11 Accordingly, we
identified all patients with an index MI during the study
period and then restricted our cohort to patients in the
ACTION Registry–GWTG who were 65 years or older
at the time of their index MI or who were aged 50 or
older at the time of the index MI with one or more additional risk factors of prior MI, diabetes mellitus on oral
medications or insulin, or known multivessel coronary
disease. Although PEGASUS also included patients aged
50 or older with an additional risk factor of non-end-stage
chronic renal dysfunction, ACTION Registry–GWTG
data are insufficiently granular to identify patients with
this additional risk factor.
In accordance with PEGASUS enrolment criteria,
we excluded patients receiving chronic anticoagulation at discharge from the index MI and patients with
prior stroke, coronary artery bypass grafting (CABG) in
the past 5 years or renal failure requiring dialysis. The
ACTION Registry–GWTG lacks data for several comorbid
conditions that were exclusion criteria for PEGASUS. As
a result, we could not identify patients with a history of
gastrointestinal bleed in the past 6 months, surgery in the
past 30 days, central nervous system tumour, intracranial
vascular abnormality, prior intracranial haemorrhage or
severe liver disease that would have been excluded from
the PEGASUS trial.
The final analytic cohort included patients eligible for
the PEGASUS trial with at least 3 years of prescription
claims after the cohort eligibility date.
Use of P2Y12 inhibitors 1 year post-MI
Patients were categorised as users of a P2Y12 inhibitor at
1 year post-MI if they had a pharmacy claim for a P2Y12
inhibitor in the first 3 months that followed 1 year from
the index MI. This approach was repeated in years 2 and
3 to establish continued use of P2Y12 inhibitors. Because
aspirin is available over the counter, the concurrent use
of aspirin could not be reliably confirmed.
Bradley SM, et al. Open Heart 2017;4:e000580. doi:10.1136/openhrt-2016-000580
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Statistical analysis
We identified patients from the ACTION Registry–
GWTG who met PEGASUS inclusion and exclusion
criteria and compared the cohort with patients from the
PEGASUS trial. Among patients eligible for PEGASUS
in the ACTION Registry–GWTG, we then compared
patient demographics (age, sex, race/ethnicity and
insurance status), comorbidities (hypertension, hyperlipidaemia, diabetes, tobacco use, prior MI, prior
percutaneous coronary intervention (PCI), prior
CABG, prior heart failure, cerebrovascular disease,
chronic kidney disease, chronic lung disease and
anaemia), clinical presentation (STEMI or NSTEMI),
management (PCI, CABG or medical management
alone) and estimated bleeding risk, by the use of P2Y12
inhibitors at 1 year after the index MI. Bleeding risk
was estimated through the application of a previously
validated model from the ACTION Registry–GWTG.17
We then assessed the current use of P2Y12 inhibitors at
1, 2 and 3 years post-MI in our cohort and the specific
P2Y12 inhibitors used. Cohort differences were assessed
using analysis of variance for continuous variables and
χ² test for categorical variables.
In the cost and ischaemic clinical consequences analysis,
we first determined the cost of increasing the use of P2Y12
inhibitors in the eligible cohort. We estimated the cost of
placing all patients eligible for PEGASUS who were not
on a P2Y12 inhibitor at year 1 post-MI on ticagrelor for a
3-year time horizon, as reported in the clinical trial. The
cost of ticagrelor was estimated based on the Wholesale
Acquisition Cost. Generally, Wholesale Acquisition Cost is
the price established by the drug manufacturer before any
rebates, discounts, allowances or other price concessions
are offered by the supplier of the product. We also estimated the cost of clopidogrel therapy in all patients eligible
for PEGASUS who were not on a P2Y12 inhibitor at year 1
post-MI using the same methods.
To estimate the ischaemic clinical consequences of
placing all patients eligible for PEGASUS who were not
on a P2Y12 inhibitor at year 1 post-MI on ticagrelor, we
applied the point estimate for the clinical effect reported
in the PEGASUS trial over a 3-year time horizon.11 We
estimated the number of prevented cardiovascular
events due to ticagrelor therapy by multiplying eligible
patients by the average effect size for cardiovascular
events reported in the PEGASUS trial (1.27% 3-year absolute risk reduction). Because a randomised comparison
of the clinical effect of clopidogrel versus ticagrelor in
stable patients with post-MI has yet to be completed and
the point estimate for the clinical effect of clopidogrel in
a post hoc analysis of the CHARISMA (Clopidogrel for
High Atherothrombotic Risk and Ischemic Stabilization,
Management, and Avoidance) trial (30-month absolute
risk reduction of 1.7%) is larger than that reported for
ticagrelor in PEGASUS, we estimated the clinical consequences of adding clopidogrel therapy by applying the
same point estimate used in our base case evaluation of
Bradley
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ticagrelor.4 Clopidogrel was chosen for this analysis given
prior studies of this therapy in similar clinical settings to
the PEGASUS trial and because clopidogrel is available
as a generic medication. In sensitivity analyses, we varied
the estimated clinical efficacy of these P2Y12 therapies
by 25% above and below the point estimate from the
randomised trials to provide a range of the potential cost
consequences of expanding therapy. We applied similar
methods in the estimation of additional bleeding events
related to increased ticagrelor use (1.24% 3-year absolute bleeding risk increase with ticagrelor 60 mg in the
PEGASUS trial).
RESULTS
We identified 273 328 patients with an index MI in the
ACTION Registry–GWTG during the period of study.
After applying inclusion and exclusion criteria from the
PEGASUS trial, 112 222 (41.1%) of these patients met
enrolment criteria for the trial (figure 1). We were able
to match 83 871 (74.7%) of these patients to Symphony
pharmaceutical claims data to assess P2Y12 inhibitor
use between 1 and 3 years post-MI. Characteristics for
patients for the PEGASUS trial randomised to 60 mg ticagrelor are descriptively compared with patients eligible
for PEGASUS in the ACTION Registry–GWTG in table 1
without statistical tests of significance, given the lack of
patient-level data from the PEGASUS trial for the present
study. Patients eligible for PEGASUS in the ACTION
Registry–GWTG appeared to be older, were more often
female, less often presented with a STEMI and were more
likely to suffer an MI or stroke in the 3-year follow-up.
At 1-year post-MI, 23 042 (27.5%) of patients eligible
for PEGASUS in the ACTION Registry–GWTG were on a
P2Y12 inhibitor. The majority of patients on a P2Y12 inhibitor were on clopidogrel (79.2%), followed by prasugrel
(17.7%) and ticagrelor (3.0%). Patient characteristics
by use of P2Y12 inhibitors at 1 year post-MI are shown in
table 2. Given the size of our cohort, many differences were
statistically significant, although the absolute differences
were generally small, with some exceptions. Compared
with patients who were not on a P2Y12 inhibitor at 1 year
post-MI, patients on a P2Y12 inhibitor were more likely
to have private insurance (30.7% vs 23.2%, p <0.001) or
received PCI with a drug-eluting stent (65.5% vs 36.9%)
and less likely to have prior MI (16.5% vs 19.7%, p <0.001)
or anaemia (17.9% vs 24.6%). Compared with patients
who were not on a P2Y12 inhibitor at 1 year, estimated
bleeding risk was slightly lower among patients on P2Y12
therapy (moderate risk 27.5% vs 30.1%, high risk 2.4% vs
4.0%; p <0.001).
The number of patients on a P2Y12 inhibitor declined
over time to 9661 (11.5%) at 2 years post-MI and 5246
(6.3%) at 3 years post-MI (figure 2). Characteristics of
patients on a P2Y12 inhibitor at 1, 2 and 3 years post-MI
were largely similar (table 3).
The Wholesale Acquisition Cost for a 1-year supply
of 60 mg ticagrelor two times per day was US$3750.
3
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Figure 1 Identification of patients eligible for PEGASUS in the ACTION Registry–GWTG (Acute Coronary Treatment and
Intervention Outcomes Network Registry–Get With The Guidelines) and analysis cohort. SHS, Symphony Health Solutions.

The estimated cost of initiating and continuing ticagrelor for a 3-year time horizon in 60 829 patients
who were eligible for the PEGASUS trial but not on a
P2Y12 inhibitor at 1-year post-MI was US$684 million.
The estimated number of cardiovascular deaths, MI
or strokes averted over a 3-year time horizon by initiation of ticagrelor in this population was 773, which
translates into a cost of US$885 000 per cardiovascular
event averted. In the sensitivity analysis, when the estimated clinical efficacy was varied by 25% above and
below the point estimate reported in the PEGASUS
trial, the cost per cardiovascular event averted ranged
from US$709 000 to US$1.2 million. The estimated
number of additional bleeding events over a 3-year
time horizon following initiation of ticagrelor in this
population was 754.
The Wholesale Acquisition Cost for a 1-year supply
of 75 mg generic clopidogrel daily was US$84, with
an estimated total cost of US$15.3 million to initiate
and continue clopidogrel in the same population of
60 829 patients for a 3-year time horizon. Estimating a
similar number of cardiovascular deaths, MI or strokes
averted as would be achieved with ticagrelor over a
3-year time horizon, this translates into US$19 800 per
cardiovascular event averted. In the sensitivity analysis, when the estimated clinical efficacy was varied by
25% above and below the point estimate, the cost per
cardiovascular event averted ranged from US$15 800
to US$26 400.
4

DISCUSSION
We assessed the implications of the PEGASUS-TIMI 54
trial in a real-world population of patients drawn from
the ACTION Registry–GWTG, including the number
of eligible patients, current use of P2Y12 inhibitors and
the cost and ischaemic consequences of long-term
P2Y12 inhibition. Among 273 328 patients with MI in the
ACTION Registry–GWTG, 112 222 (41.1%) met eligibility for the PEGASUS trial. Among patients eligible
for PEGASUS, only 27.5% were on a P2Y12 inhibitor
at 1 year post-MI. Initiating and continuing ticagrelor
in patients eligible for PEGASUS who were not yet on
a P2Y12 inhibitor at 1-year post-MI would cost an estimated US$885 000 per MI, stroke or death averted over
a 3-year time horizon. The cost per ischaemic event
averted was much lower for generic clopidogrel. These
findings suggest that P2Y12 inhibitors are not routinely
used in long-term care of patients with a prior history of
MI. Adoption of the PEGASUS strategy in clinical practice would result in a large increase in P2Y12 use, and
the cost per cardiovascular event averted would vary
dramatically with the choice of P2Y12 inhibitor.
Evidence supporting long-term P2Y12 use in patients with
prior myocardial infarction
Although a number of studies have investigated the
long-term use of DAPT after PCI, investigation of
the clinical efficacy of DAPT in long-term management of patients with a prior MI is more limited. The
Bradley SM, et al. Open Heart 2017;4:e000580. doi:10.1136/openhrt-2016-000580
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Table 1 Comparison of patients eligible for the PEGASUS
(60 mg ticagrelor with patients eligible for PEGASUS
identified from the ACTION Registry-GWTG

PEGASUS trial
patients
(n=7045)

PEGASUS
trial eligible in
the ACTION
Registry–GWTG
(n=83 871)

 Age, mean (SD)

65.2 (8.4)

69.4 (9.5)

 Men, n (%)

5384 (76.4)

51 117 (60.9)

 White

6077 (86.3)

73 232 (87.3)

 Diabetes, n (%)

2308 (32.8)

29 704 (35.4)

 Hypertension, n (%)
 Peripheral arterial
disease, n (%)

5461 (77.5)

64 472 (76.9)

368 (5.2)

6401 (7.6)

Characteristics
Patient demographics

Patient medical history

1168 (16.6)
 Prior MI, n (%)
 Chronic kidney disease,
n (%)
1547/6955 (22.2)
  ≥Stage 3
MI characteristics and
management

15 763 (18.8)

25 551 (30.5)

 Presentation, n (%)
  STEMI

3757/7035 (53.4)

33 609 (40.1)

  NSTEMI

2842/7035 (40.4)

50 262 (59.9)

 Beta-blocker

5796 (82.3)

77 552 (92.5)

 ACE inhibitor or ARB

5631 (79.9)

57 352 (68.4)

 Statin

6495 (92.2)

77 181 (92.0)

 Aspirin at any dose
Ischaemic outcomes at 3
years

7036 (99.9)

81 155 (96.8)

 MI
 Stroke

285 (4.5%)
91 (1.5%)

10 889 (13.0%)
1447 (1.7%)

Medications

ACTION Registry–GWTG, Acute Coronary Treatment and
Intervention Outcomes Network Registry–Get With The Guidelines;
ARB, angiotensin II receptor blocker; MI, myocardial infarction;
NSTEMI, non-ST-elevation myocardial infarction; STEMI, STelevation myocardial infarction.

CHARISMA trial failed to demonstrate a clinical benefit
from long-term clopidogrel use when added to aspirin
in a broad population of patients with elevated cardiovascular risk.3 However, a subgroup analysis of this trial
suggested a potential benefit of P2Y12 inhibitor use
among patients with a prior history of MI.4 These findings were supported by the PEGASUS-TIMI 54 trial, in
which the addition of ticagrelor to background aspirin
therapy resulted in a 1.27% reduction in the rate of
cardiovascular death, MI or stroke among patients with
a remote history of MI and an additional risk factor.7
In both studies, the addition of long-term P2Y12 inhibition was not associated with a reduction in all-cause
Bradley
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mortality. However, given the implications for ischaemic
events, clinical practice guidelines state the continuation of DAPT may be reasonable among patients with a
prior MI between 1 and 3 years earlier who have tolerated DAPT without bleeding complications.6
Applicability of the PEGASUS trial to real-world practice
Despite the potential benefit of long-term P2Y12 inhibitors therapy in patients with prior MI, the number
of patients who might benefit is unknown. The population evaluated in clinical trials may not represent
the population of patients in clinical practice. In the
present study, less than half of all patients with MI met
the PEGASUS eligibility criteria. These findings are
consistent with prior studies that have demonstrated
the differences between patients represented in clinical
trials and patients seen in clinical practice.12
Indiscriminate use of P2Y12 inhibitors among
patients with a prior MI may result in the treatment
of a lower risk population than represented by the
PEGASUS trial and, potentially, a smaller effect on
ischaemic events. In the present study, one in five
patients with prior MI was not PEGASUS eligible,
because the patient lacked an additional high-risk
feature for ischaemic events. Furthermore, nearly
14% of patients were ineligible, because they were on
an anticoagulant. The use of P2Y12 inhibitors in these
patients may result in significantly higher bleeding
risk, which outweighs the ischaemic benefit of P2Y 12
inhibitors. These findings highlight the importance
of close scrutiny of eligibility as it applies to individual
patients in routine practice.
Long-term use of P2Y12 inhibitors after myocardial infarction
in clinical practice
P2Y12 inhibitors were infrequently used in the longterm management of patients with MI in the ACTION
Registry–GWTG. It will be important to study the potential changing use of this therapy over time to understand
the clinical effectiveness and safety of P2Y12 inhibitors in
real-world settings, both among patients who meet eligibility criteria for the randomised trials of this therapy
and among the more than 50% of patients with prior MI
who are not represented in the randomised trials of this
therapy. In addition, our study suggests that non-clinical factors such as insurance status influences the use
of P2Y12 in current practice. Identifying and addressing
barriers to the use of P2Y12 inhibitors will be important
to guide optimal use in eligible patients. Further, we
found patients at higher bleeding risk were less likely
to receive long-term P2Y12 inhibitors in current practice. This is consistent with the thoughtful use of P2Y12
inhibitors, as a trade-off between decreasing ischaemic
risk and increasing bleeding risk is intrinsic to the longterm use of P2Y12 inhibitors. Ensuring P2Y12 inhibitors
are used in patients with higher predicted ischaemic
benefit and lower bleeding risk may further ensure
5
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Table 2 Characteristics of patients eligible for PEGASUS in the ACTION Registry–GWTG by P2Y12 use 1 year after MI
Overall cohort
(n=83 871)

On DAPTat1 year post-MI
(n=23 042)

NoDAPT 1 year post-MI
(n=60 829)

p Value

 Age, mean (SD)

69.4 (9.5)

69.3 (9.0)

69.4 (9.6)

0.03

 Men, n (%)

51 117 (60.9)

14 165 (61.5)

36 952 (60.7)

0.06

  White

73 232 (87.3)

20 562 (89.2)

52 670 (86.6)

<0.001

  African-American

8067 (9.6)

1 858 (8.1)

6209 (10.2)

<0.001

  Asian

1525 (1.8)

390 (1.7)

1135 (1.9)

0.09

  Other

1047 (1.3)

232 (1.0)

815 (1.3)

<0.001

 Hispanic or Latino, n (%)

4415 (5.3)

1066 (4.6)

3349 (5.5)

<0.001

  None

6037 (7.2)

672 (2.9)

5365 (8.8)

<0.001

  Private

21 176 (25.2)

7069 (30.7)

14 107 (23.2)

<0.001

  Medicaid or Medicare

55 595 (66.3)

15 127 (65.6)

40 468 (66.5)

0.02

  Other

1063 (1.3)

174 (0.8)

889 (1.5)

<0.001

 Body mass index, mean (SD)

29.4 (9.4)

29.7 (10.4)

29.3 (9.0)

<0.001

 Diabetes, n (%)
  Insulin therapy, n (%)

29 704 (35.4)

7497 (32.5)

22 207 (36.5)

<0.001

6262 (7.5)

1370 (5.9)

4892 (8.0)

<0.001

 Hypertension, n (%)

64 472 (76.9)

17 196 (74.6)

47 276 (77.7)

<0.001

 Dyslipidaemia, n (%)

43 458 (51.8)

11 941 (51.8)

31 517 (51.8)

0.98

 Current/recent smoker, n (%)

23 253 (27.7)

5948 (25.8)

17 305 (28.4)

<0.001

 Cerebrovascular disease, n (%)

3742 (4.5)

882 (3.8)

2860 (4.7)

<0.001

 Peripheral arterial disease, n (%)

6401 (7.6)

1465 (6.4)

4936 (8.1)

<0.001

 Prior PCI, n (%)

17 094 (20.4)

4336 (18.8)

12 758 (21.0)

<0.001

 Prior CABG, n (%)

267 (0.3)

58 (0.3)

209 (0.3)

0.04

 Prior MI, n (%)

15 763 (18.8)

3807 (16.5)

11 956 (19.7)

<0.001

 Prior heart failure, n (%)

5615 (6.7)

996 (4.3)

4619 (7.6)

<0.001

  Stage 1 or 2

57 663 (68.8)

16 761 (72.7)

40 902 (67.2)

<0.001

  ≥Stage 3
 Anaemia, n (%)

25 551 (30.5)

6075 (26.4)

19 476 (32.0)

<0.001

19 062 (22.7)

4115 (17.9)

14 947 (24.6)

<0.001

 Chronic lung disease, n (%)

9723 (11.6)

2143 (9.3)

7580 (12.5)

<0.001

  STEMI

33 609 (40.1)

11 146 (48.4)

22 463 (36.9)

<0.001

  NSTEMI

50 262 (59.9)

11 896 (51.6)

38 366 (63.1)

<0.001

 PCI, n (%)

55 973 (66.7)

19 852 (86.2)

36 121 (59.4)

<0.001

  DES

37 510 (44.7)

15 085 (65.5)

22 425 (36.9)

<0.001

  BMS

14 460 (17.2)

3872 (16.8)

10 588 (17.4)

0.04

 CABG

10 463 (12.5)

949 (4.1)

9514 (15.6)

<0.001

  Very low

12 262 (14.8)

3529 (15.6)

8733 (14.6)

<0.001

  Low
  Moderate

42 931 (51.9)
24 291 (29.4)

12 336 (54.4)
6226 (27.5)

30 595 (51.0)
18 065 (30.1)

<0.001
<0.001

Characteristics
Patient demographics

 Race, n (%)

 Insurance, n (%)

Patient medical history

 Chronic kidney disease, n (%)

MI characteristics and management
 Presentation, n (%)

 Bleeding Risk Score, n (%)

Continued
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Table 2 Continued
Overall cohort
(n=83 871)

On DAPTat1 year post-MI
(n=23 042)

NoDAPT 1 year post-MI
(n=60 829)

p Value

2931 (3.6)
239 (0.3)

546 (2.4)
43 (0.2)

2385 (4.0)
196 (0.3)

<0.001
0.001

  None

19 111 (22.8)

1238 (5.4)

17 873 (29.4)

<0.001

  Clopidogrel

51 075 (60.9)

17 297 (75.1)

33 778 (55.5)

<0.001

  Ticlopidine

71 (0.1)

19 (0.1)

52 (0.1)

0.89

  Prasugrel

13 355 (15.9)

4394 (19.1)

8961 (14.7)

<0.001

  Ticagrelor

375 (0.4)

139 (0.6)

236 (0.4)

<0.001

Beta-blocker

77 552 (92.5)

21 559 (93.6)

55 993 (92.0)

<0.001

ACE inhibitor or ARB

57 352 (68.4)

16 539 (71.8)

40 813 (67.1)

<0.001

Statin

77 181 (92.0)

21 782 (94.5)

55 399 (91.1)

<0.001

Aspirin at any dose

81 155 (96.8)

22 548 (97.9)

58 607 (96.3)

<0.001

  None

60 829 (72.5)

0 (100.0)

60 829 (100.0)

  Clopidogrel

18 255 (21.8)

18 255 (79.2)

0

  Ticlopidine

9 (0.0)

9 (0.0)

0

  Prasugrel

4089 (4.9)

4089 (17.7)

0

  Ticagrelor

693 (0.8)

693 (3.0)

0

  Warfarin

1832 (2.2)

397 (1.7)

1435 (2.4)

<0.001

  Dabigatran

139 (0.2)

41 (0.2)

98 (0.2)

0.59

  Rivaroxaban

95 (0.1)

20 (0.1)

75 (0.1)

0.16

  Apixiban

4 (0.0)

0 (0.0)

4 (0.0)

0.22

Beta-blocker

42 597 (50.8)

17 723 (76.9)

24 874 (40.9)

<0.001

ACE inhibitor or ARB
Statin

33 658 (40.1)
41 273 (49.2)

13 994 (60.7)
17 797 (77.2)

19 664 (32.3)
23 476 (38.6)

<0.001
<0.001

Characteristics
  High
   Very high
Discharge medications
P2Y12 inhibitor, n (%)

Medications at 1 year
P2Y12 inhibitor

Anticoagulation

ACTION Registry–GWTG, Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With The Guidelines; ARB,
angiotensin II receptor blocker; BMS, bare-metal stent; CABG, coronary artery bypass grating; DAPT, dual antiplatelet therapy; DES, drugeluting stent; MI, myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI,
ST-elevation MI.

optimal patient outcomes with this therapy in clinical
practice.7 18
Although the focus of our study relates to the implications of increasing the use of DAPT beyond 1 year post-MI,
it is worth noting that 23% of patients in the ACTIONGWTG Registry did not receive a P2Y12 inhibitor at the
time of discharge. This gap in care delivery is consistent
with prior studies19–21 and suggests an opportunity to
improve patient outcomes through more consistent use
of P2Y12 at discharge for MI.
Cost and clinical consequences of long-term P2Y12 inhibitor
use
Although the PEGASUS trial specifically evaluated ticagrelor, the CHARISMA substudy suggests a potential
Bradley
SM, et al. Open Heart 2017;4:e000580. doi:10.1136/openhrt-2016-000580


class effect of long-term P2Y12 inhibition among patients
with prior MI.4 This finding has important implications
for the costs of expanding P2Y12 use in clinical practice.
Clopidogrel has been available as a generic medication
since 2012 and is less expensive than ticagrelor. As a
result, the estimated cost per ischaemic event averted
differs by nearly 45-fold between the two alternatives.
The cost relative to clinical impact of a given therapy
is becoming increasingly relevant, as payers apply these
considerations in coverage decisions and provider
organisations with Accountable Care Organization
contracts seek to optimise outcomes at lower cost.22
Based on data from the Healthcare Utilization Project,
the median cost of MI admissions in the USA in 2013 was
US$15 402, and the median cost of stroke admissions
7
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Figure 2 Proportion of patients eligible for PEGASUS in the ACTION Registry–GWTG (Acute Coronary Treatment and
Intervention Outcomes Network Registry–Get With The Guidelines) on P2Y12 inhibitors over time. MI, myocardial infarction.

was US$8949.23 With this as a comparator, the cost of
additional clopidogrel use would be nearly offset by the
cost of averted events, whereas the cost of additional
ticagrelor use would be more than the cost of averted
events. However, once the cost of bleeding events are
considered, both therapies may be more costly than
discontinuation of P2Y12 inhibitors. Additional studies
from clinical practice are needed to further inform the
effectiveness of these two therapies on ischaemic events
and the cost consequences of specific P2Y12 inhibitors
used in long-term management.
Strengths and limitations
Strengths of this study include the national perspective and pharmacy claims data to evaluate long-term
P2Y12 use in clinical practice. Limitations of our study
include the lack of detailed clinical data in follow-up
from the index MI, thus requiring extrapolation of clinical data at the time of the MI to estimate eligibility for
the PEGASUS trial. As a result, our study may underestimate the proportion of patients who would have been
excluded from the PEGASUS trial. We were also unable
to adjust for important differences in patient selection
necessary to perform comparative effectiveness analyses between use and non-use of P2Y12 inhibitors and
different P2Y12 inhibitors. We lacked data on some
comorbid conditions that were exclusion criteria for the
PEGASUS trial. As a result, our study may overestimate
the proportion of real-world patients who would have
met eligibility criteria for the PEGASUS trial. We were
unable to match 25% of patients eligible for PEGASUS
to pharmacy claims data. Our study is limited by a time
period that precedes the publication of the PEGASUS
trial in 2014. However, the intent of our study was to
8

describe how clinical practice might be influenced by
this study, and future studies are needed to understand
practice changes in P2Y12 inhibitor use subsequent to
the publication of this trial. Although we compared the
estimated ischaemic clinical consequences of increasing
the use of long-term P2Y12 therapy, increased bleeding
is a risk of long-term use of this therapy. However,
differences in the reporting of bleeding events across
the PEGASUS trial and the CHARISMA substudy limit
the ability to extrapolate the estimated impact beyond
what has been reported in these trials. We were limited
in our evaluation to ischaemic events using point estimates from the randomised controlled trials for the
time horizons studied. Further study of P2Y12 therapies
in routine clinical practice is needed to further understand the ischaemic benefit and bleeding risk trade-offs
of these therapies in real-world use. Finally, we did not
attempt to convert clinical consequences to health utilities (ie, quality-adjusted life years), as our intent was to
describe the costs and ischaemic clinical consequences
of expanding P2Y12 inhibitor use rather than the cost-effectiveness of the therapy.
CONCLUSION
A minority of patients in the ACTION Registry–GWTG
were on a P2Y12 inhibitor beyond 1 year post-MI.
Applying PEGASUS trial findings to our patient cohort
would result in a large increase in P2Y12 inhibitor use.
The estimated cost per ischaemic event averted is
nearly 45-fold larger with long-term ticagrelor than
with generic clopidogrel. Continued study of longterm P2Y12 inhibition on patient outcomes and cost
of care is needed to further guide optimal use of this
therapy.
Bradley SM, et al. Open Heart 2017;4:e000580. doi:10.1136/openhrt-2016-000580
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Table 3 Patients eligible for PEGASUS in the ACTION Registry–GWTG characteristics by the use of a P2Y12 inhibitor at 1, 2
and 3 years post-MI
On P2Y12 at
1 year post-MI
(n=23 042)

On P2Y12 at
2 years post-MI
(n=9661)

On P2Y12 at
3 years post-MI
(n=5246)

p Value

 Age, mean (SD)

69.3 (9.0)

69.3 (9.1)

69.1 (8.9)

0.53

 Men, n (%)

14 165 (61.5)

5890 (61.0)

3194 (60.9)

0.57

  White

20 562 (89.2)

8527 (88.3)

4639 (88.4)

0.02

  African-American

1858 (8.1)

848 (8.8)

446 (8.5)

0.09

  Asian

390 (1.7)

189 (2.0)

107 (2.0)

0.10

  Other

232 (1.0)

97 (1.0)

54 (1.0)

0.99

Hispanic or Latino, n (%)

1066 (4.6)

494 (5.1)

274 (5.2)

0.05

Characteristics
Patient demographics

 Race, n (%)

 Insurance, n (%)
  None

672 (2.9)

284 (2.9)

166 (3.2)

0.63

  Private

7069 (30.7)

2 916 (30.2)

1 558 (29.7)

0.32

  Medicaid or Medicare

15 127 (65.6)

6 387 (66.1)

3 482 (66.4)

0.51

174 (0.8)

74 (0.8)

40 (0.8)

0.99

 Body mass index

29.7 (10.4)

29.9 (11.3)

30.0 (11.2)

0.22

 Diabetes, n (%)
 Insulin therapy, n (%)

7497 (32.5)

3257 (33.7)

1759 (33.5)

0.08

1370 (5.9)

590 (6.1)

320 (6.1)

0.82

 Hypertension, n (%)

17 196 (74.6)

7455 (77.2)

4040 (77.0)

<0.001

 Dyslipidaemia, n (%)

11 941 (51.8)

5117 (53.0)

2763 (52.7)

0.13

 Current/recent smoker, n (%)

5948 (25.8)

2588 (26.8)

1445 (27.5)

0.02

 Cerebrovascular disease, n (%)

882 (3.8)

399 (4.1)

214 (4.1)

0.38

 Peripheral arterial disease, n (%)

1465 (6.4)

652 (6.7)

347 (6.6)

0.39

 Prior PCI, n (%)

4336 (18.8)

1935 (20.0)

1045 (19.9)

0.02

 Prior CABG, n (%)

58 (0.3)

26 (0.3)

12 (0.2)

0.89

 Prior MI, n (%)

3807 (16.5)

1733 (17.9)

947 (18.1)

0.001

 Prior heart failure, n (%)

996 (4.3)

439 (4.5)

213 (4.1)

0.37

  Stage 1 or 2

16 761 (72.7)

6988 (72.3)

3855 (73.5)

0.32

  ≥Stage 3
 Anaemia, n (%)

6075 (26.4)

2578 (26.7)

1346 (25.7)

0.40

4115 (17.9)

1786 (18.5)

956 (18.2)

0.38

 Chronic lung disease, n (%)

2143 (9.3)

886 (9.2)

459 (8.7)

0.46

  STEMI

11 146 (48.4)

4661 (48.2)

2542 (48.5)

0.96

  NSTEMI

11 896 (51.6)

5000 (51.8)

2704 (51.5)

0.96

 PCI indication, n (%)

19 852 (86.2)

8102 (83.9)

4379 (83.5)

<0.001

  DES

15 085 (65.5)

6112 (63.3)

3280 (62.5)

<0.001

  BMS

3872 (16.8)

1564 (16.2)

844 (16.1)

0.25

  CABG

949 (4.1)

471 (4.9)

268 (5.1)

<0.001

3529 (15.6)
12 336 (54.4)

1404 (14.8)
5170 (54.4)

749 (14.5)
2852 (55.1)

0.06
0.53

  Other
Patient medical history

 Chronic kidney disease, n (%)

MI characteristics and management
 Presentation, n (%)

 Bleeding Risk Score, n (%)
  Very low
  Low

Continued
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Table 3 Continued

Characteristics

On P2Y12 at
1 year post-MI
(n=23 042)

On P2Y12 at
2 years post-MI
(n=9661)

On P2Y12 at
3 years post-MI
(n=5246)

  Moderate

6226 (27.5)

2693 (28.3)

1438 (27.8)

  High
   Very high

546 (2.4)
43 (0.2)

214 (2.3)
24 (0.3)

122 (2.4)
11 (0.2)

p Value
0.28
0.70
0.53

ACTION Registry–GWTG, Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With The Guidelines; ARB,
angiotensin II receptor blocker; BMS, bare-metal stent; CABG, coronary artery bypass grating; DES, drug-eluting stent; MI, myocardial
infarction; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation MI.
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